Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy

NCT06770257 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped The project was terminated as the genetic office did not approve it.

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG: daunorubicin, cytarabine liposomes
DRUG: Azacitidine
DRUG: Venetoclax

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

[object Object]